![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, December 27, 2021 3:56:17 PM
Between July 16, 2021 and November 4, 2021 Regen Biopharma, Inc. (the “Company”) has satisfied $967,830 of principal indebtedness on convertible notes payable and $539,392 in fees, penalties and interest accrued but unpaid on convertible notes payable through the issuance of 706,451,543 of the Company’s common shares, 23,720,548 of the Company’s Series A Preferred shares and payment to noteholders of $218,529 in cash. As of June 30, 2021 the Company had convertible notes payable with an outstanding principal balance of $2,364,075 and as of November 4, 2021 the Company had convertible notes payable with an outstanding principal balance of $1,396,245.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM